Business Context and Reporting Period
This Form 8-K filing by Pavmed Inc. reports on events occurring on June 21, 2022, specifically the results of the Company's 2022 Annual Meeting of Stockholders. The filing details the election of directors, approval of corporate governance matters, and amendments to the Company's charter.
Key Financial Metrics
This filing is a current report regarding corporate governance and does not contain financial statements. Consequently, data regarding revenue, profit, cash flow, margins, debt, and liquidity are not provided in this document.
Material Changes and Corporate Actions
- Director Elections: Stockholders elected three Class C directors (Lishan Aklog, M.D., Michael J. Glennon, and Joan B. Harvey) to serve until the third succeeding annual meeting. All management nominees were elected.
- Convertible Notes Approval: Stockholders approved the issuance of common stock under the Senior Secured Convertible Notes issued pursuant to the Securities Purchase Agreement dated March 31, 2022, to satisfy Nasdaq Listing Rule 5635.
- Charter Amendment: Stockholders approved an amendment to the Certificate of Incorporation to increase the total number of authorized common shares from 150,000,000 to 250,000,000. The amendment was filed with the Delaware Secretary of State and became effective on June 21, 2022.
- Executive Compensation: The advisory "say-on-pay" proposal was approved. Stockholders also selected a frequency of three years for future say-on-pay votes.
- Auditor Ratification: The appointment of Marcum LLP as the independent registered public accounting firm for the year ending December 31, 2022, was ratified.
Guidance, Outlook, and Risks
The filing does not contain management guidance, financial outlook, or specific risk factors. It references the Definitive Proxy Statement (filed May 2, 2022) for fuller descriptions of the convertible notes transaction and the charter amendment.
Investor Verification Checklist
- Verify the terms of the Senior Secured Convertible Notes (March 2022 Notes) referenced in the filing, specifically regarding the conversion mechanics and potential dilution.
- Review the Definitive Proxy Statement filed on May 2, 2022, for detailed financial context regarding the convertible notes transaction.
- Confirm the updated authorized share count of 250,000,000 in subsequent filings to monitor potential future issuances.
- Check the Company's most recent 10-K or 10-Q for actual financial performance metrics, as this 8-K contains no financial data.